Skip to main content

Summary

for females ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with metastatic HR-positive, HER2-negative breast cancer who have progressed during or following first-line metastatic treatment with a cyclin-dependent kinase (CDK) 4/6 inhibitor such as palbociclib, ribociclib, or abemaciclib. The study will be performed in two stages. During Stage 1, participants will be randomized to fulvestrant (control) or an atezolizumab-containing doublet or triplet combination. Those who experience disease progression, loss of clinical benefit, or unacceptable toxicity may be eligible to receive a new triplet combination treatment in Stage 2 until loss of clinical benefit or unacceptable toxicity. New treatment arms may be added and/or existing treatment arms may be closed during the course of the study on the basis of ongoing clinical efficacy and safety as well as the current treatments available.

Official Title

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)

Keywords

Breast Neoplasms Bevacizumab Fulvestrant Exemestane Tamoxifen Antibodies Antibodies, Monoclonal Hormones Estradiol

Eligibility

You can join if…

Open to females ages 18 years and up

for Both Stages:

  • Measureable disease per RECIST v1.1 with tumor accessible for biopsy
  • Adequate hematologic and end organ function

Inclusion Criteria for Stage 1:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Metastatic or inoperable, locally advanced, histologically or cytologically confirmed invasive HR-positive HER2-negative breast cancer
  • Recommended for endocrine therapy, and cytotoxic chemotherapy not indicated at study entry
  • Recurrence or progression following most recent systemic breast cancer therapy
  • Disease progression during or after CDK4/6 inhibitor treatment for metastatic disease
  • Postmenopausal according to protocol-defined criteria
  • Life expectancy >3 years
  • Available tumor specimen for determination of PD-L1 status

Inclusion Criteria for Stage 2:

  • ECOG performance status of 0-2
  • Ability to initiate treatment within 3 months after disease progression or unacceptable toxicity on a Stage 1 regimen

You CAN'T join if...

for Both Stages:

  • Significant or uncontrolled comorbid disease as specified in the protocol
  • Uncontrolled tumor-related pain
  • Autoimmune disease except for stable/controlled hypothyroidism, Type 1 diabetes mellitus, or certain dermatologic conditions
  • Positive human immunodeficiency virus or hepatitis B or C
  • Severe infection within 4 weeks and/or antibiotics within 2 weeks prior to study treatment
  • Prior allogeneic stem cell or solid organ transplantation
  • History of malignancy other than breast cancer within 2 years prior to screening except those with negligible risk of metastasis/death
  • History of or known hypersensitivity to study drug or excipients

Exclusion Criteria for Stage 1:

  • HER2-positive breast cancer
  • Prior fulvestrant or cytotoxic chemotherapy for metastatic breast cancer, or certain other agents as specified in the protocol
  • Unresolved AEs from prior anti-cancer therapy

Exclusion Criteria for Stage 2:

  • Unacceptable toxicity with atezolizumab during Stage 1
  • Uncontrolled cardiovascular disease or coagulation disorder, including use of anticoagulants as specified in the protocol
  • Significant abdominal or intestinal manifestations within 6 months prior to treatment
  • Proteinuria

Locations

  • UCSF Helen Diller Family CCC not yet accepting patients
    San Francisco, California, 94115, United States
  • Providence Cancer Center not yet accepting patients
    Portland, Oregon, 97231, United States
  • Northwest Medical Specialties, PLLC; Research Department not yet accepting patients
    Tacoma, Washington, 98405, United States
  • Tennessee Oncology; Sarah Cannon Cancer Center not yet accepting patients
    Nashville, Tennessee, 37203, United States
  • University of Alabama at Birmingham not yet accepting patients
    Birmingham, Alabama, 35249, United States
  • University of Michigan not yet accepting patients
    Ann Arbor, Michigan, 48109-0934, United States
  • Northwest Georgia Oncology Centers PC - Marietta not yet accepting patients
    Marietta, Georgia, 30060, United States
  • University of Pittsburgh Medical Center Health System; Dept. of Newborn Medicine not yet accepting patients
    Pittsburgh, Pennsylvania, 15213, United States
  • Levine Cancer Institute not yet accepting patients
    Charlotte, North Carolina, 28204, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center not yet accepting patients
    Baltimore, Maryland, 21231, United States
  • Memorial Sloan Kettering Cancer Center not yet accepting patients
    New York, New York, 10065, United States
  • Yale University School Of Medicine; Yale Cancer Center not yet accepting patients
    Trumbull, Connecticut, 06611, United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Hoffmann-La Roche
ID
NCT03280563
Phase
Phase 1/2
Lead Scientist
Study Type
Interventional
Last Updated
September 11, 2017
I’m interested in this study!